SELLAS Life Sciences Group, Inc.
11.54USD
+0.1900 (+1.67%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SLS.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.05▲ | -$0.06 | 0 | 0 |
| Next quarter | -$0.05▲ | -$0.06 | 0 | 0 |
| Current year | -$0.2▲ | -$0.21 | 0 | 0 |
| Next year | -$0.1▲ | -$0.15 | 1 | 0 |
Beat in 2 of the last 3
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.05 | -$0.05 | -0.01 (-11.1%) |
| 2025-12-31 | -$0.06 | -$0.05 | +0.01 (+21.0%) |
| 2025-09-30 | -$0.08 | -$0.06 | +0.02 (+21.7%) |
13 ratings from 5 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Maxim Group | Maintained | Buy | $7 $10 | Mar 12, 2026 |
| Maxim Group | Maintained | Buy | $4 $7 | Jul 16, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | $3 | Nov 22, 2023 |
| Cantor Fitzgerald | Reiterated | Overweight | $3 | Sep 7, 2023 |
| Alliance Global Partners | Maintained | Buy | $14 $8 | Nov 15, 2022 |
| Cantor Fitzgerald | Maintained | Overweight | $10 $6 | Jun 28, 2022 |
| Cantor Fitzgerald | Initiated | Overweight | $18 | Jul 21, 2021 |
| Maxim Group | Upgraded from Hold | Buy | $12 | Nov 15, 2019 |
| Alliance Global Partners | Initiated | Buy | $4.5 | Apr 8, 2019 |
| Oppenheimer | Initiated | Outperform | $13 | Nov 1, 2018 |
| Maxim Group | Maintained | Buy | $13 $5 | Jul 20, 2018 |
| HC Wainwright & Co. | Initiated | Buy | $11 | Apr 2, 2018 |
| Maxim Group | Upgraded from Hold | Buy | — | Mar 19, 2018 |
20 filings from 8 insiders · 0 buy / 0 sell over 6m
Officers and directors of SLS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STERGIOU ANGELOS MChief Executive Officer | Grant | 1.06M | — | — | Jun 16, 2026 |
| WASMAN JANEDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| CICIC DRAGANOfficer | Grant | 300.0k | — | — | Jan 7, 2026 |
| BURNS JOHN THOMASChief Financial Officer | Grant | 300.0k | — | — | Jan 7, 2026 |
| KALIN KATHERINE BACHDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| VARIAN JOHN WDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| VAN NOSTRAND ROBERT LDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| SCHEINBERG DAVID ADirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| KALIN KATHERINE BACHDirector | Buy | 63.4k | $1.59 | $101k | Nov 19, 2025 |
| VAN NOSTRAND ROBERT LDirector | Buy | 10.0k | $1.48 | $15k | Jun 12, 2025 |
| WASMAN JANEDirector | Buy | 20.0k | $1.69 | $34k | May 30, 2025 |
| KALIN KATHERINE BACHDirector | Buy | 20.0k | $1.80 | $36k | May 22, 2025 |
| WASMAN JANEDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| CICIC DRAGANOfficer | Grant | 194.3k | — | — | Jan 10, 2025 |
| BURNS JOHN THOMASChief Financial Officer | Grant | 194.3k | — | — | Jan 10, 2025 |
| STERGIOU ANGELOS MChief Executive Officer | Grant | 500.9k | — | — | Jan 10, 2025 |
| KALIN KATHERINE BACHDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| VARIAN JOHN WDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| VAN NOSTRAND ROBERT LDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| SCHEINBERG DAVID ADirector | Grant | 12.5k | — | — | Jan 10, 2025 |
No analyst notes on SLS yet.
Analyst Ratings
2 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 1 | 0 | 0 | 0 | Buy1.50 |
| 1 mo ago | 1 | 1 | 0 | 0 | 0 | Buy1.50 |
Members whose judged calls on SLS have played out most reliably.
No settled calls on SLS yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice